TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: T-cell DNA synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in serum 25OH-vitamin D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in docosahexaenoic acid (DHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recurrent ankle sprains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migratory behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: easy injection, impossible aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catheter-related bloodstream infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Global satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MRI scan pauses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to depressive episode recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to manic/hypomanic/mixed episode recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient involvement in studies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recurrent hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antral follicle count (AFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of effective labour analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of breakthrough pain
Endpoint domain: Adverse events/effects
Primary endpoint: resumption of normal daily activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alleviation of handicap imposed by dizziness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urinary Distress Inventory‐Irritative scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 70% greater improvement in UI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained progression of disability
Endpoint domain: Mortality/survival
Primary endpoint: Rate of clinical relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulation of new or enlarging hyperintense lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ELF volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom-related functional impairment improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of fasciculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core temperature at end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound edge temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density (BMD) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychomotor function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HTN control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean % |Delta Fru|
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain rating of the 4 mm PN
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for 4 mm PN
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean blood pressure readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of tumor necrosis factor‐α, interleukin‐6, and C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time to recovery of respiratory muscle paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evacuation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Regular intestinal habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global discomfort index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Airway Pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and duration of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of convulsive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with treatment‐resistant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotion dysregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax for dl-MPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial area under the plasma concentration curve from 4 to 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular complications at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: All cause and cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: mean changes in visual acuity letter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentages of eyes with stable or improved vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children with positive AntiHBs level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean concentration (GMC) of AntiHBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VE/VCO2 ratio during submaximal exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver function indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrolyte levels (K+, Na+, Cl−, Ca2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory markers (CRP, IL-6, TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma exposure of OC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma exposure of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant safety findings
Endpoint domain: Adverse events/effects
Primary endpoint: T2 quantitation for detecting IVDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs of the dissecting sealer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IQ point difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Healing of duodenal ulcer at four weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: independence at 3 and 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: serum CgA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes towards date rape
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-Reported Outcomes Measurement Information System Physical Health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Activation Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in medication regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained virological response at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with analgesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortisol levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Supplemental analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to diagnosis of type 1 diabetes
Endpoint domain: Mortality/survival
Primary endpoint: GDF15 levels as a biomarker for metformin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metformin dose prediction based on GDF15 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less moderate hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: shorter period of bradypnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Eye doctor-confirmed DFE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of aortic wall neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of aortic wall cytotoxic T-cell content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DAS28 (4) improvement of >1.2 units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of myalgias/arthralgias
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of drug-related thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Bracket loss
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in mobility on the SPPB
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: decreases in binge-eating or eating-disorder psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean emergence agitation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of severe emergence agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement rates between ODK-0702 and control kits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3/4 Hematologic Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ovarian hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prolongation of the menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Response ratio (MMSE 3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vitality Index total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of accidental falls
Endpoint domain: Adverse events/effects
Primary endpoint: nutrition knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: label perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flap retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pulmonary accumulation of Tc-99m MAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to achieve Ramsay score 03
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coughing during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of furcation involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of re-instrumentation
Endpoint domain: Adverse events/effects
Primary endpoint: pulp response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dentin bridge formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratings of depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: skin irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: patch loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ETS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GHQ‐28 cutoff score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea with walking and climbing stairs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean time required to enter epidural space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clarity of epidural space identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rates of EA or CSEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median concentration of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease relapse rate
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White blood cell counts after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: C-reactive protein levels after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of needle passes for block performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Enhanced motor block at the 5‐min assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative neurological symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: stage IV tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: extranodal occurrence in the oral cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: tumor necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: LMS (Lactate Measurement Speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in serum HCVRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of recurrent dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cumulative incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: umbilical cord blood pO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: umbilical cord blood lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Jebsen Taylor Hand Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl‐Meyer Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased prevalence of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Small for gestational age at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe adverse perinatal outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum concentration (Cmax) of alendronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Severity Index (ISI) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rates of insomnia (ISI < 8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean overall satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean sensitivity for grading stenosis > or = 70%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean specificity for grading stenosis > or = 70%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean maximum serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug deposition in the respiratory tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maxillary Vertical Bone Fill (MVBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nociceptive Outcome Measure (NOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No reflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Corrected TIMI frame count < 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in quiet breathing pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased ventilation per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory and expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of mutans streptococci in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in chronic low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCD diagnostic status and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed AUC within +/- 20% of target value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise/physical health benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of lithotripsy (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer health care contacts
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: fewer school absences
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: less interference with household activities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Total number of therapy interruptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: GCS use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DVT rates
Endpoint domain: Adverse events/effects
Primary endpoint: Virologic response at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: workload scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrillation Organization Index (FOI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HAMA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcomes (ACR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KT-2000 side-to-side laxity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to sport activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Donor-site morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of corticosteroid regimens in treating mild to moderate croup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased dyspnoea over 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of paroxysmal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of heart failure/death
Endpoint domain: Mortality/survival
Primary endpoint: Crusting/scabbing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Epithelial confluence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes